Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,574 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-hodgkin Lymphoma Clear all
Completed Phase 1 Interventional

Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma

NCT01768338
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Ofatumumab combined with SB-485232
Drug
Lead sponsor
Michael John Robertson
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Nov 10, 2026, 5:47 PM EST
Not listed Phase 1 Interventional

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

NCT05415098
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
Interventions
APG-5918
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Springdale, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Nov 10, 2026, 5:47 PM EST
Recruiting Phase 3 Interventional

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

NCT07516093
View directory record Official record
Conditions
B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
NX-5948, Pirtobrutinib
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
6
States / cities
Macon, Georgia • Fort Wayne, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 10, 2026, 5:47 PM EST
Not yet recruiting Phase 2 Interventional

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

NCT07748364
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma
Interventions
Glofitamab
Biological
Lead sponsor
Joshua Brody
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 10, 2026, 5:47 PM EST
Terminated Phase 2 Interventional Results available

Study of Repeat Intranodal Injections of Ad-ISF35

NCT00942409
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions
ISF35
Biological
Lead sponsor
Januario Castro, M.D.
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Nov 10, 2026, 5:47 PM EST
Recruiting Phase 1Phase 2 Interventional

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

NCT07069699
View directory record Official record
Conditions
Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Lumbar Puncture, Pidnarulex, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
8
States / cities
Irvine, California • Orange, California • Fairway, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 10, 2026, 5:47 PM EST
Completed Phase 1 Interventional Results available

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Malignant Melanoma
Interventions
PF-05082566, rituximab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
35
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Nov 10, 2026, 5:47 PM EST
Completed Phase 1 Interventional

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

NCT01644799
View directory record Official record
Conditions
Recurrent Follicular Lymphoma
Interventions
idelalisib, lenalidomide
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 10, 2026, 5:47 PM EST
Not listed Phase 2 Interventional

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

NCT00022932
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Iodine-131 Anti-B1 Antibody
Drug
Lead sponsor
Corixa Corporation
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 10, 2026, 5:47 PM EST
Terminated No phase listed Observational

Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing

NCT01556828
View directory record Official record
Conditions
Cutaneous Lymphoma, Other Skin Disorders, Mycosis Fungoides, Cutaneous T-cell Lymphoma
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Nov 10, 2026, 5:47 PM EST
Not listed Phase 1 Interventional

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

NCT00515892
View directory record Official record
Conditions
Leukemia, Non-Hodgkin's Lymphoma, NHL
Interventions
Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy, Antibody Therapy, Monoclonal Antibody Therapy
Drug · Procedure
Lead sponsor
Cambridge Antibody Technology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Beverly Hills, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Nov 10, 2026, 5:47 PM EST
Completed No phase listed Observational

A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines

NCT00001571
View directory record Official record
Conditions
HIV Infections, Lymphoma, AIDS-Related, Lymphoma, Non-Hodgkin
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 10, 2026, 5:47 PM EST
Completed Phase 2 Interventional Results available

Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01733238
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's
Interventions
PNT2258
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lafayette, Indiana • Grand Rapids, Michigan • Grosse Pointe Woods, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 10, 2026, 5:47 PM EST
Completed Phase 1 Interventional

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

NCT04088864
View directory record Official record
Conditions
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
Drug
Lead sponsor
Kara Lynn Davis
Other
Eligibility
1 Year to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 10, 2026, 5:47 PM EST
Terminated Phase 3 Interventional

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

NCT05181540
View directory record Official record
Conditions
Hodgkin Lymphoma, Non Hodgkin Lymphoma
Interventions
AB-205, Placebo
Biological · Other
Lead sponsor
Angiocrine Bioscience
Industry
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
28
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Nov 10, 2026, 5:47 PM EST
Completed Phase 1 Interventional

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05824585
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
DZD8586
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 10, 2026, 5:47 PM EST
Terminated Phase 1 Interventional Results available

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT03136497
View directory record Official record
Conditions
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
400mg ABT-199, Ibrutinib, Rituximab, 800mg ABT-199
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Nov 10, 2026, 5:47 PM EST
Active, not recruiting Phase 1 Interventional

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)

NCT00368082
View directory record Official record
Conditions
Lymphoma, Hodgkin's Disease, Relapse, Lymphoma, Non-Hodgkin
Interventions
TGFbeta resistant LMP-specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2031
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 10, 2026, 5:47 PM EST
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

NCT01585688
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
hLL1-DOX (IMMU-115)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Newark, Delaware • Orlando, Florida • Goshen, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Nov 10, 2026, 5:47 PM EST
Completed No phase listed Observational

Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function

NCT03351140
View directory record Official record
Conditions
Neoplasms
Interventions
Qualitative Interviews, PROMIS Physical Function Items
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Nov 10, 2026, 5:47 PM EST
Completed No phase listed Observational

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

NCT00001582
View directory record Official record
Conditions
T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Nov 10, 2026, 5:47 PM EST
Terminated Phase 2 Interventional Results available

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

NCT01220297
View directory record Official record
Conditions
Hematologic Diseases, Acute-graft-versus-host Disease, Leukemia, Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma
Interventions
Sirolimus, Mycophenolate mofetil (MMF), Carmustine, Etoposide, Cyclophosphamide (Cyclo, CY), FTBI
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Nov 10, 2026, 5:47 PM EST
Completed Phase 3 Interventional Results available

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

NCT01728805
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
KW-0761, Vorinostat
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
34
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Nov 10, 2026, 5:47 PM EST
Completed Phase 1 Interventional Results available

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

NCT00691210
View directory record Official record
Conditions
Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Vorinostat, Niacinamide, Etoposide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Nov 10, 2026, 5:47 PM EST